EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye

Aslı Bozdemir iD, Sibel Hacıoğlu iD, Gülsüm Akgün Çağlıyan iD, Nevin Alayvaz Aslan iD, Süleyman Utku Uzun iD, Kayıhan Kara, Utku Iltar, Orhan Kemal Yücel, Ünal Ataş, Selin Arslan Kirezli, Ali İhsan Gemici, İnci Alacacıoğlu und 14 weitere

Journal of Clinical Medicine · 12.08.2026 · 15 (16) · 6232

DOI: 10.3390/jcm15166232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.08.2026. Verfasst von Aslı Bozdemir und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Pamukkale University Hospital, Denizli 20070, Türkiye. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elranatamab, a bispecific antibody targeting BCMA and CD3, has demonstrated clinical activity in relapsed/refractory multiple myeloma. Real-world evidence regarding infectious complications and supportive care remains limited. We evaluated the early clinical activity, safety profile, infectious complications, and supportive care practices associated with relapsed/refractory multiple myeloma (RRMM). This study represents one of the first multicenter real-world evaluations of elranatamab in Türkiye.

Methods

This multicenter retrospective study included 87 patients with relapsed/refractory multiple myeloma treated with elranatamab. Clinical characteristics, treatment responses, immune-mediated toxicities, infectious complications, and supportive care practices were assessed. Overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated. Multivariable analyses were performed to identify factors associated with treatment response and clinical outcomes.

Results

At 3 months, ORR was 47.1% in the ITT population, 54.7% in the mITT population, and 83.7% among evaluable patients; corresponding 6-month ORRs were 31.0%, 42.2%, and 81.8%, respectively. The high proportion of patients without landmark response assessments primarily reflected insufficient follow-up, early death, or disease progression. Elevated LDH remained independently associated with lower response probability and inferior clinical outcomes. Cytokine release syndrome (CRS) occurred in 69% of patients, with grade ≥ 3 events in 5.7%, whereas immune effector cell-associated neurotoxicity syndrome (ICANS) was infrequent (4.6%) and no grade ≥ 3 events occurred. Grade ≥ 3 infections occurred in 39% of patients, including CMV events requiring antiviral treatment in 24.1%. No HBV reactivation occurred among patients receiving antiviral prophylaxis. Median PFS and OS were 8.1 and 10.6 months, respectively.

Conclusions

Elranatamab demonstrated early clinical activity and a manageable safety profile in a heavily pretreated real-world RRMM population. Infectious complications, including CMV events, remained clinically relevant, emphasizing the importance of supportive care. Longer follow-up is needed to characterize long-term outcomes.

Schlagwörter

Stichwörter der Autor:innen

bispecific antibodyelranatamabinfectious complicationsmultiple myelomareal-world data

Autor:innen und Institutionen

  • Division of Hematology, Pamukkale University Hospital, Denizli 20070, Türkiye.
  • Division of Epidemiology, Pamukkale University Hospital, Denizli 20070, Türkiye.
  • Division of Hematology, Akdeniz University Hospital, Antalya 07070, Türkiye.
  • Division of Hematology, Dokuz Eylül University Hospital, İzmir 35340, Türkiye.
  • Division of Hematology, İzmir City Hospital, İzmir 35530, Türkiye.
  • Division of Hematology, TOBB ETÜ Faculty of Medicine Hospital, Ankara 06560, Türkiye.

ORCID-Profile: Aslı Bozdemir, Sibel Hacıoğlu, Gülsüm Akgün Çağlıyan, Nevin Alayvaz Aslan, Süleyman Utku Uzun, Mustafa Kemal Yeniay, Zehra Narlı Özdemir, Ayşe Uysal

Zitieren

APA

Bozdemir, A., Hacıoğlu, S., Akgün Çağlıyan, G., Alayvaz Aslan, N., Uzun, S. U., Kara, K., Iltar, U., Yücel, O. K., Ataş, Ü., Arslan Kirezli, S., Gemici, A. İ., Alacacıoğlu, İ., Yeniay, M. K., Bilgir, O., Narlı Özdemir, Z., Haydaroğlu Şahin, H., Uysal, A., Aksöz, Z., Güven, Z. T., …, & Güler, N. (2026). Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye. Journal of Clinical Medicine, 15(16), 6232. https://doi.org/10.3390/jcm15166232

Vancouver

Bozdemir A, Hacıoğlu S, Akgün Çağlıyan G, Alayvaz Aslan N, Uzun SU, Kara K, et al. Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye. Journal of Clinical Medicine. 2026;15(16):6232. doi:10.3390/jcm15166232

BibTeX
@article{Bozdemir2026,
  author = {Bozdemir, Aslı and Hacıoğlu, Sibel and Akgün Çağlıyan, Gülsüm and Alayvaz Aslan, Nevin and Uzun, Süleyman Utku and Kara, Kayıhan and Iltar, Utku and Yücel, Orhan Kemal and Ataş, Ünal and Arslan Kirezli, Selin and Gemici, Ali İhsan and Alacacıoğlu, İnci and Yeniay, Mustafa Kemal and Bilgir, Oktay and Narlı Özdemir, Zehra and Haydaroğlu Şahin, Handan and Uysal, Ayşe and Aksöz, Zekeriya and Güven, Zeynep Tuğba and Aygün, Kemal and Tekinalp, Atakan and Yılmaz, Mehmet and Atmaca Mutlu, Cansu and Pektaş, Gökhan and Salim, Ozan and Güler, Nil},
  title = {Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {16},
  pages = {6232},
  doi = {10.3390/jcm15166232}
}
Kostenlos starten →